microbiology

PreclinicalBiologic

CCHU de Reims

microbiology is one of 2 biologic programs targeting Respiratory Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Respiratory DiseaseRecruiting

Respiratory DiseasePreclinical

Recruiting

Competition

Competitive Landscape

2 competitors in Respiratory Disease

#DrugCompanyPhaseTrials

Aspirin Challenge

RRush University Medical Center

microbiology

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2036

N/ARecruiting

Respiratory Disease

NCT02924818

Clinical

Trials by Indication[1]

Respiratory Disease1 trial

Cohort for Research and Innovation in Chronic Inflammatory Respiratory Diseases

Recruiting·CCHU de Reims·N/A·NCT02924818·225 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for microbiology. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — microbiology compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for microbiology. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CHU de Reims company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: CCHU de Reims

microbiology

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2036

Trials by Indication[1]

Respiratory Disease1 trial

References

Drug Info

Quick Facts

Related News